| Pfizer Mitigates Tanezumab Risk with Potential US$1.8 B Deal with Eli Lilly |
Abstract
|
|
Heather Cartwright |
|
| Roche Signals Return to Antibiotics Development with Polyphor Licensing Deal |
Abstract
|
|
Heather Cartwright |
|
| Endo Looks to Geographic Expansion and Tax Advantages with US$1.6 B Paladin Buyout |
Abstract
|
|
Heather Cartwright |
|
| Salix Adds to Gastroenterology Franchise with US$2.6 B Santarus Acquisition |
Abstract
|
|
Heather Cartwright |
|
| Shire Progresses Rare Disease Strategy with US$4.2 B ViroPharma Purchase |
Abstract
|
|
Heather Cartwright |
|
